GREENLAND MINES LTD Income (Loss) from Equity Method Investments
GREENLAND MINES LTD (GRML) reported Income (Loss) from Equity Method Investments of -$78.95 thousand for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-10-18.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-10-18
- GREENLAND MINES LTD income (loss) from equity method investments for fiscal 2022 was -$78.95K.
| Period end | Income (Loss) from Equity Method Investments 12 month |
|---|---|
| 2022-12-31 | -$78.95K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |